Anavex Life Sciences Corp.
AVXLHealthcare|Biotechnology|US
$1.15
+0.04 (+3.60%)
DCF Value
$1.17
Tangible Book / Share
$1.23
Cash / Share
$1.29
Clinical Trials (13)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06245213 A Study of ANAVEX3-71 in Adults With Schizophrenia | Schizophrenia | P2 | Active | 71 | RCT, Double-blind | ANAVEX3-71 oral capsules, Placebo oral capsules |
| NCT04304482 ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome | Rett Syndrome | P2P3 | Completed | 92 | RCT, Double-blind | ANAVEX2-73 oral liquid, Placebo oral liquid |
| NCT04314934 OLE of Phase 2b/3 Study ANAVEX2-73-AD-004 | Alzheimer Disease | P2P3 | Completed | 300 | Open-label | ANAVEX2-73 |
| NCT03790709 ANAVEX2-73 for Treatment of Early Alzheimer's Disease | Alzheimer Disease | P2P3 | Completed | 509 | RCT, Double-blind | High dose ANAVEX2-73, Mid dose ANAVEX2-73, Placebo oral capsule |
| NCT03941444 ANAVEX2-73 Study in Patients With Rett Syndrome | Rett Syndrome | P3 | Completed | 33 | RCT, Double-blind | ANAVEX2-73, Placebo |
| NCT02756858 An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease | Alzheimer's Disease | P2 | Completed | 21 | Open-label | ANAVEX2-73 |
| NCT03758924 Study of ANAVEX2-73 in Patients With Rett Syndrome | Rett Syndrome | P2 | Completed | 31 | RCT, Double-blind | ANAVEX2-73, Placebo |
| NCT03774459 ANAVEX2-73 Study in Parkinson's Disease Dementia | Parkinsons Disease With Dementia | P2 | Completed | 132 | RCT, Double-blind | High dose ANAVEX2-73, Mid dose ANAVEX2-73, Placebo oral capsule |
| NCT02244541 Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease | Alzheimer's Disease | P2 | Completed | 32 | RCT, Open-label | ANAVEX2-73 Oral, ANAVEX2-73 Intravenous, ANAVEX2-73 Oral, ANAVEX2-73 Oral |
| NCT04575259 OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001 | Parkinson Disease Dementia | P2 | Completed | 132 | Open-label | ANAVEX2-73 |
| NCT04442945 Phase 1 Study of ANAVEX3-71 | Healthy | P1 | Completed | 36 | RCT, Double-blind | ANAVEX3-71, Placebo |
| NCT04025502 Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Healthy Volunteer Subjects | Schizophrenia | Completed | 161 | — | — | |
| NCT04928703 Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers | Healthy | Early P1 | Completed | 33 | RCT, Double-blind | Ketamine |